🟢 GILD.BA gains 0.4% as positive HIV trial results and European Trodelvy approval buoy sentiment

GILD.BA is trading 0.4% up today at $53,775, driven by significant company-specific news:

• Gilead announced successful Phase 3 trial results for its once-weekly long-acting HIV treatment regimen.
• European regulators granted first-line monotherapy approval for the company's cancer drug Trodelvy.
• The stock also continues to benefit from an HSBC upgrade to Buy earlier this week, with the bank citing an undervalued pipeline.